시장보고서

상품코드

1509785

세계의 말초 액체 색전제 시장 규모 및 예측, 세계 및 지역별 점유율, 동향, 성장 기회 분석 - 유형별, 용도별, 지역별

Peripheral Liquid Embolic Agents Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type, Application, and Geography

발행일: 2024년 06월 | 리서치사:

The Insight Partners | 페이지 정보: 영문 233 Pages | 배송안내 : 즉시배송

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 말초 액체 색전제 시장 규모는 2023년 4,042만 달러에 달할 것으로 예상되며, 2023-2031년 연평균 9.1% 성장하여 2031년에는 8,141만 달러에 달할 것으로 예상됩니다.

말초 액체 색전제는 중재적 방사선 시술에서 누출된 혈관이나 기형을 막는 데 사용되는 물질입니다. 이 약물은 주입 후 응고되어 혈전을 형성하여 표적 부위로의 혈류를 차단합니다.

온도 유도 상변화 시스템과 pH 트리거 색전제 시장 개척이 시장 성장 추세로 작용하고 있습니다.

액체색전술은 생체공학, 특히 말초 시술에서 큰 관심을 받고 있습니다. 액체 색전제는 코일이나 카테터가 도달할 수 없는 말초, 병변 또는 원위부까지 침투할 수 있습니다. 현재 사용되는 액체 색전제는 대부분의 임상적 요구를 충족시킬 수 있지만 몇 가지 단점이 있습니다. 이에 따라 영상 특성 개선, 합병증 감소, 유동 경로 성능 최적화, 약물 부하 실현 등을 목표로 다양한 새로운 액체 색전제가 개발되고 있습니다. 최소침습적 영상화 분야에서 임상적으로 조정된 색전제를 개발하기 위해서는 관련 부작용(독성, 접착력 등), 생체 기능성(생체 적합성, 생분해성, 생역학, 생리활성), 방사선 투과성 등 더 중요한 재료 특성을 체계적으로 조사하는 것이 필수적입니다.

온도에 민감한 고분자 용액은 체내에서 실온에서 졸 주입 가능한 상태에서 겔 상태로 변합니다. 2015년 Qian 등이 Journal of Controlled Release에 발표한 연구에 따르면, 폴리(N-이소프로필아크릴아미드)(PNIPAAm)는 32℃의 하한 임계 용액 온도(LCST)에 반응하여 가역적인 상전이 현상이 발생합니다. 이오헥솔 분산액을 사용한 폴리(N-이소프로필아크릴아미드-코-부틸메틸아크릴레이트) 겔은 토끼에서 신장 동맥의 효과적인 색전증과 독소루비신의 서방성을 보여주었습니다. 마찬가지로, 2011년 Wang 등이 National Library of Medicine에 발표한 연구에 따르면 키토산/B-글리세롤린산(C/GP)은 토끼의 신장 동맥을 성공적으로 폐쇄하여 색전제로서의 가능성을 보여주었습니다. 마찬가지로, 2011년 Wiley Online Library에 게재된 연구에 따르면, Zhao 등은 색전증에 대한 온도 민감성 PNIPAAm-iohexol 나노겔을 조사했습니다. 상전이 온도(36.5 ℃) 이상의 소수성 상호 작용을 통해 in situ 혈관 주조를위한 계층 적 3D 젤 네트워크가 형성되었습니다. 나노겔은 말초색전제인 리피오돌과 비교하여 토끼 VX2 간종양에서 더 우수한 말초색전 효과를 보였습니다.

또한, 폴록사머407(폴리에틸렌옥사이드a-폴리프로필렌옥사이드b-폴리에틸렌옥사이드a의 삼중 블록 공중합체)을 함유한 감온성 액체색전 하이드로겔이 간암 치료를 위해 제안되고 있습니다. 폴록사머 407, 하이드록시메틸셀룰로오스, 알긴산나트륨, 요오디옥사놀로 구성된 복합 하이드로겔(PSHI)은 온도 상승에 따라 유동성 졸과 수축 겔의 2상을 보였습니다. 특히 PSHI-Ca2를 사용한 VX2 간암 모델에서 색전술 후 종양이 사라져 완전한 폐색을 입증했습니다.

pH에 민감한 활성 성분은 in vitro 환경과 생리적 환경 사이의 pH 변화로 인해 상전이 현상이 일어납니다. 이러한 하이드로겔은 pH에 반응하여 부풀어 오르거나 분해되며, 이는 약물 방출을 조절하는 데 사용됩니다.

Nguyen 등이 2016년 Royal Society of Chemistry에 발표한 연구에 따르면, 간세포암의 TACE를 위해 폴리(호오-카프로락톤-코락티도)(PCLA), PEG, 폴리(우레탄 설파이드 설파메타딘)(PUSSM)으로 구성된 공동 중합체인 PCLA-PUSSM이 개발되었습니다. 중합체인 PCLA-PUSSM이 개발되었습니다. 이 생분해성 물질은 독소루비신을 담지하고 pH의 감소에 반응하여 상전이 현상을 보였습니다. 이 하이드로겔은 독소루비신의 서방성을 나타내면서 VX2 토끼 종양 모델에서 간종양을 성공적으로 색전시켰습니다. 쥐 모델에서 색전술은 종양에 대한 혈액 공급을 차단하여 저산소증으로 인한 산성 환경을 형성하고 젖산증을 유발했습니다. 낮은 pH는 약물 방출을 유도하여 in vivo에서 종양의 성장을 억제하는 데 성공했습니다.

온도 민감성 및 pH 트리거로 테스트중인 액체 색전제 중 일부는 다음과 같습니다.

표 1. 온도 민감성 및 pH 트리거 겔화 테스트 중 액체 색전제

액체 색전제 메커니즘의 장점, 고전적 사용 시나리오 또는 테스트 조건

키토산/B-글리세롤린산(키토산/B-GP) 온도 및 pH 트리거 겔화 약물전달 토끼의 신장 동맥

온도 트리거 겔화 약물전달 토끼의 VX2 원발성 간 종양

폴리(N- 이소 프로필 아크릴 아미드-코-부틸 메틸 아크릴 레이트) 나노 겔(PIB 나노 겔) 온도 유발 겔화 리피오돌보다 우수한 색전 효과 토끼의 VX2 간 종양 원발성 부위

Poloxamer 407 온도 유도 겔화 일시적 혈관 폐색 개 신장 동맥

Poloxamer407,알긴산나트륨,히드록시메틸셀룰로오스,요오디옥사놀,칼슘이온(PSHI-Ca2) 온도 유도 겔화 방사선 투과성 토끼 원발성 VX2 간종양

설파 메타 진 기반 하이드로 겔 pH 트리거 겔화 약물전달 토끼의 VX2 간암 원발성 간 종양 원발성 부위

폴리(아미노 에스테르 우레탄) 블록 폴리머(PEAU) 온도 및 pH 트리거 겔화 약물전달 토끼에서 VX2 간 종양의 원발성 부위

이러한 온도 유발 상변화 시스템과 pH 유발 색전제에 대한 관심과 신흥국 시장 개척은 향후 몇 년 동안 말초 액체 색전제 시장에 새로운 트렌드를 가져올 것으로 예상됩니다.

말초 액체 색전제 시장 분석은 유형, 용도, 지역별로 세분화하여 분석하였습니다. 유형별로 말초 액체 색전제 시장은 중합형 액체 색전제와 침전형 액체 색전제로 구분됩니다. 용도별로는 말초 액체 색전제 시장은 엔드리크 II형, 기형, 출혈 및 외상, 정맥류, 종양, 내장 동맥류로 분류됩니다.

말초 액체 색전제 시장 조사 범위는 북미(미국, 캐나다, 멕시코), 유럽(스페인, 영국, 독일, 프랑스, 이탈리아, 기타 유럽), 아시아태평양(한국, 중국, 일본, 인도, 호주, 기타 아시아태평양), 중동 및 아프리카(남아프리카공화국, 사우디아라비아, 아랍에미리트, 기타 중동 및 아프리카), 중남미(브라질, 아르헨티나, 기타 중남미) 등입니다. 북미는 전 세계 말초 액체 색전제 시장에서 가장 큰 기여를 하고 있습니다. 아시아태평양은 2023-2031년 동안 시장에서 가장 높은 CAGR을 보일 것으로 예상됩니다.

북미의 시장 성장은 동맥류, 외상 및 기타 사례의 증가에 기인합니다. 캐나다 시장은 말초 장애에 대한 우려 증가에 대응하기 위한 정부 지원 증가로 인해 성장할 것으로 예상됩니다. 멕시코 시장은 제약 산업과 의료 관광의 성장으로 인해 성장할 것으로 추정됩니다. 아시아태평양 말초 액체 색전제 시장은 중국, 일본, 인도, 호주, 한국 및 기타 아시아태평양으로 구분됩니다. 아시아태평양의 시장 성장은 말초동맥질환(PAD) 유병률 증가, 최소침습 수술에 대한 수요 증가, 병원 및 외래 수술 센터 수 증가, 시장 기업의 신흥 국가에 대한 관심 증가, 아시아태평양의 의료 인프라 개발 등 다양한 요인에 의해 주도되고 있습니다.

미국 질병통제예방센터(CDC), 유럽의약품청(EMA), 범미보건기구(PAHO), 세계보건기구(WHO)는 말초 액체 색전제 시장에 대한 보고서를 작성할 때 참고한 1차 및 2차 정보 중 일부입니다.

말초 액체 색전제 시장 - 주요 시장 역학
시장 성장 촉진요인
- 말초혈관 질환 발생률 증가
- 최소침습 시술에 대한 수요 증가
시장 성장 억제요인
- 색전약의 고비용
시장 기회
- 시장 기업에 의한 전략적 이니셔티브 상승
향후 동향
- 온도 야기 상변화 시스템과 pH트리거색전약 개발
영향 분석

제6장 말초 액체 색전제 시장 : 세계 시장 분석

말초 액체 색전제 시장 판매량, 2021-2031년
말초 액체 색전제 시장 분석
시장 상황 분석, 2023년

제7장 말초 액체 색전제 시장 분석 : 유형별

중합성 액체 색전제
침전형 액체 색전제

제8장 말초 액체 색전제 시장 분석 : 용도별

Endoleak II형
기형
출혈 및 외상
정맥류
종양
내장 동맥류

제9장 말초 액체 색전제 시장 : 지역별 분석

북미
- 캐나다
- 멕시코
유럽
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 기타 유럽
아시아태평양
- 중국
- 일본
- 인도
- 호주
- 한국
- 기타 아시아태평양
중동 및 아프리카
- 사우디아라비아
- 남아프리카공화국
- 아랍에미리트
- 기타 중동 및 아프리카
중남미
- 브라질
- 아르헨티나
- 기타 중남미

제10장 산업 상황

말초 액체 색전제 시장의 성장 전략
무기적 성장 전략
유기적 성장 전략

제11장 기업 개요

Medtronic Plc
B Braun SE
Guerbet SA
Sirtex Medical Ltd
Balt
MicroVention Inc
Johnson & Johnson
GEM srl

제12장 부록

ksm 24.07.15

The peripheral liquid embolic agents market is expected to grow from US$ 40.42 million in 2023 to US$ 81.41 million by 2031; it is anticipated to record a CAGR of 9.1% from 2023 to 2031.

Peripheral liquid embolic agents are substances used in interventional radiology procedures to block leaking blood vessel and malformations. These agents solidify after injecting which forms plug and block the blood flow to the targeted area.

Developments in Temperature-Induced Phase Change Systems and pH-Triggered Embolic Agents Acts as a Trend for Market Growth

Liquid embolism is a topic of great interest in bioengineering, particularly in peripheral procedures. Liquid embolic agents can penetrate peripheral, nidus, or distal areas where coils or catheters cannot reach. Although currently used liquid embolic agents can meet most clinical needs, they have some shortcomings. Therefore, various novel liquid embolic agents have been developed to improve imaging characteristics, reduce complications, optimize flow performance, and achieve drug loading capability. The systematic investigation of additional important material characteristics such as associated side effects (e.g., toxicity and adhesion), biofunctional (biocompatibility, biodegradability, biomechanics, and bioactivity), and radiopacity is essential for the development of clinically tailored embolic agents in the field of minimally invasive imaging procedures.

Temperature-sensitive polymer solutions can change from a sol-injectable state to a gel state at room temperature in the body. Poly(N-isopropyl acrylamide) (PNIPAAm) exhibits a reversible phase transition in response to a lower critical solution temperature (LCST) of 32 °C. According to a study published in the Journal of Controlled Release by Qian et al. in 2015, poly(N-isopropylacrylamide-co-butylmethyl acrylate) gels with iohexol dispersions for TACE of liver cancer demonstrated effective embolization of renal arteries in rabbits and sustained release of doxorubicin. Similarly, as per a study published in the National Library of Medicine by Wang et al. in 2011, chitosan/B-glycerophosphate (C/GP) successfully closed renal arteries in rabbits, indicating to be a potential embolization agent. Likewise, Zhao et al. also investigated temperature-sensitive PNIPAAm-iohexol nano gels for embolization, according to a research study published Wiley Online Library in 2011. The hydrophobic interactions above the phase transition temperature (36.5 °C) lead to a hierarchical 3D gel network for in situ vessel casting. Compared to Lipiodol, a peripheral embolic agent, the nanogel provided better peripheral embolization in VX2 liver tumors in rabbits.

Furthermore, a poloxamer 407 (a triblock copolymer of polyethylene oxide a-polypropylene oxide b-polyethylene oxide a) containing a thermosensitive liquid embolic hydrogel has been proposed for liver cancer therapy. This composite hydrogel composed of poloxamer 407, hydroxymethyl cellulose, sodium alginate, and iodixanol (PSHI) presented two phases with increasing temperature: a flowing sol and a shrunken gel. Notably, complete occlusion of the VX2 liver cancer model was demonstrated with PSHI-Ca2+ as the tumor disappeared after embolization.

pH-sensitive active ingredients undergo a phase transition due to the pH change between the in vitro and physiological environments. These hydrogels swell and collapse in response to pH, which is used to control drug release.

As per a study published in the Royal Society of Chemistry by Nguyen et al. in 2016, PCLA-PUSSM, a copolymer consisting of poly(ε-caprolactone-co-lactide) (PCLA), PEG, and poly(urethane sulfide sulfamethazine) (PUSSM) was developed, for TACE of HCC. This biodegradable material was loaded with doxorubicin and exhibited a phase transition in response to decreasing pH. The hydrogel successfully embolized a liver tumor from a VX2 rabbit tumor model while providing a sustained release of doxorubicin. In a rat model, embolization stopped blood supply to the tumor, creating an acidic environment through hypoxia and inducing lactic acidosis. The low pH triggered drug release and successfully inhibited tumor growth in vivo.

Some of the liquid embolic agents under trial for temperature-sensitive and pH-triggered are given below:

Table 1. Liquid Embolic Agents Under Trial for Temperature-Sensitive and pH-Triggered Gelation

Liquid Embolic Agents Mechanism Advantage Classical Usage Scenarios or Trial Conditions

Chitosan/B- glycerophosphate (chitosan/B-GP) Temperature- and pH-triggered gelation Drug delivery Renal arteries in rabbits

Silk-Elastin-Like proteins (SELPs) Temperature- triggered gelation Drug delivery Primary VX2 liver tumors in rabbit

Poly(N-isopropylacrylamide-co-butyl methylacrylate) nanogel (PIB nanogel) Temperature- triggered gelation A better embolization than lipiodol Primary VX2 liver tumors in rabbit

Poloxamer 407 Temperature- triggered gelation Temporary vascular occlusion Renal arteries in canines

poloxamer 407, sodium alginate, hydroxymethyl cellulose, iodixanol, and calcium ions (PSHI-Ca2+) Temperature- triggered gelation Radiopacity Primary VX2 liver tumors in rabbit

Sulfamethazine-based hydrogel pH-triggered gelation Drug delivery Primary VX2 liver tumors in rabbit

Poly(Amino Ester Urethane) block polymer (PEAU) Temperature- and pH-triggered gelation Drug delivery Primary VX2 liver tumors in rabbit

Thus, the growing focus and developments on temperature-induced phase change systems and pH-triggered embolic agents are expected to bring new trends in the peripheral liquid embolic agents market in the coming years.

The peripheral liquid embolic agents market analysis has been carried out by considering the following segments: type, application and geography. Based on type, the peripheral liquid embolic agents market is bifurcated into polymerizing liquid embolic agents and precipitating liquid embolic agents. In terms of application, the peripheral liquid embolic agents market is classified into endoleak type II, malformations, bleedings and trauma, varicose vein, tumors, and visceral aneurysm..

The scope of the peripheral liquid embolic agents market report covers North America (the US, Canada, and Mexico), Europe (Spain, the UK, Germany, France, Italy, and the Rest of Europe), Asia Pacific (South Korea, China, Japan, India, Australia, and the Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). North America is the biggest contributor to the global peripheral liquid embolic agents market. Asia Pacific is predicted to show the highest CAGR in the market during 2023-2031.

The North America regional market growth is attributed to the increasing cases of aneurysms, trauma, and others across the region. The market in Canada is anticipated to grow because of rising government support for addressing the increasing concerns regarding peripheral disorders. The market in Mexico is estimated to grow owing to the growing pharma industries and medical tourism. The Asia Pacific peripheral liquid embolic agents market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. The market growth in the region is driven by various factors such as the rising prevalence of peripheral artery diseases (PAD), increasing demand for minimally invasive procedures, growing number of hospitals and ambulatory surgery centers, rising focus on developing countries by market players , and developing healthcare infrastructure in Asia Pacific

Centers for Disease Control and Prevention (CDC), European Medicines Agency (EMA), The Pan American Health Organization (PAHO), and World Health Organization (WHO) are a few key primary and secondary sources referred to while preparing the report on the peripheral liquid embolic agents market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:

4. Peripheral Liquid Embolic Agents Market Landscape

4.1 Overview
4.2 PEST Analysis
4.3 Regional Pricing Analysis, 2023

5. Peripheral Liquid Embolic Agents Market - Key Market Dynamics

5.1 Peripheral Liquid Embolic Agents Market - Key Market Dynamics
5.2 Market Drivers
- 5.2.1 Rising Incidence of Peripheral Vascular Diseases
- 5.2.2 Increasing Demand for Minimally Invasive Procedures
5.3 Market Restraints
- 5.3.1 High Cost of Embolization Agents
5.4 Market Opportunities
- 5.4.1 Growing Strategic Initiatives by Market Players
5.5 Future Trends
- 5.5.1 Developments in Temperature-Induced Phase Change Systems and pH-Triggered Embolic Agents
5.6 Impact analysis

6. Peripheral Liquid Embolic Agents Market - Global Market Analysis

6.1 Peripheral Liquid Embolic Agents Market Revenue (US$ Thousand), 2021-2031
6.2 Peripheral Liquid Embolic Agents Market Analysis
6.3 Market Positioning Analysis, 2023

7. Peripheral Liquid Embolic Agents Market Analysis - by Type

7.1 Polymerizing Liquid Embolic Agent
- 7.1.1 Overview
- 7.1.2 Polymerizing Liquid Embolic Agent: Peripheral Liquid Embolic Agents Market - Revenue and Forecast to 2031 (US$ Thousand)
7.2 Precipitating Liquid Embolic Agent
- 7.2.1 Overview
- 7.2.2 Precipitating Liquid Embolic Agent: Peripheral Liquid Embolic Agents Market - Revenue and Forecast to 2031 (US$ Thousand)

8. Peripheral Liquid Embolic Agents Market Analysis - by Application

8.1 Endoleak Type II
- 8.1.1 Overview
- 8.1.2 Endoleak Type II: Peripheral Liquid Embolic Agents Market - Revenue and Forecast to 2031 (US$ Thousand)
8.2 Malformations
- 8.2.1 Overview
- 8.2.2 Malformations: Peripheral Liquid Embolic Agents Market - Revenue and Forecast to 2031 (US$ Thousand)
8.3 Bleedings and Trauma
- 8.3.1 Overview
- 8.3.2 Bleedings and Trauma: Peripheral Liquid Embolic Agents Market - Revenue and Forecast to 2031 (US$ Thousand)
8.4 Varicose Vein
- 8.4.1 Overview
- 8.4.2 Varicose Vein: Peripheral Liquid Embolic Agents Market - Revenue and Forecast to 2031 (US$ Thousand)
8.5 Tumours
- 8.5.1 Overview
- 8.5.2 Tumours: Peripheral Liquid Embolic Agents Market - Revenue and Forecast to 2031 (US$ Thousand)
8.6 Visceral Aneurysm
- 8.6.1 Overview
- 8.6.2 Visceral Aneurysm: Peripheral Liquid Embolic Agents Market - Revenue and Forecast to 2031 (US$ Thousand)

9. Peripheral Liquid Embolic Agents Market - Geographical Analysis

9.1 North America
- 9.1.1 North America Peripheral Liquid Embolic Agents Market Overview
- 9.1.2 North America: Peripheral Liquid Embolic Agents Market - Revenue and Forecast to 2031 (US$ Thousand)
  - 9.1.2.1 North America: Peripheral Liquid Embolic Agents Market - Revenue and Forecast Analysis - by Type
  - 9.1.2.2 North America: Peripheral Liquid Embolic Agents Market - Volume and Forecast Analysis - by Type
    - 9.1.2.2.1 North America: Peripheral Liquid Embolic Agents Market - Revenue and Forecast Analysis - by Polymerizing Liquid Embolic Agent
    - 9.1.2.2.2 North America: Peripheral Liquid Embolic Agents Market - Volume and Forecast Analysis - by Polymerizing Liquid Embolic Agent
    - 9.1.2.2.3 North America: Peripheral Liquid Embolic Agents Market - Revenue and Forecast Analysis - by Precipitating Liquid Embolic Agent
    - 9.1.2.2.4 North America: Peripheral Liquid Embolic Agents Market - Volume and Forecast Analysis - by Precipitating Liquid Embolic Agent
  - 9.1.2.3 North America: Peripheral Liquid Embolic Agents Market - Revenue and Forecast Analysis - by Application
- 9.1.3 North America: Peripheral Liquid Embolic Agents Market - Revenue and Forecast Analysis - by Country
  - 9.1.3.1 Canada: Peripheral Liquid Embolic Agents Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 9.1.3.1.1 Canada: Peripheral Liquid Embolic Agents Market Breakdown, by Type
    - 9.1.3.1.1.1 Canada: Peripheral Liquid Embolic Agents Market Breakdown, by Polymerizing Liquid Embolic Agent
    - 9.1.3.1.1.2 Canada: Peripheral Liquid Embolic Agents Market Breakdown, by Precipitating Liquid Embolic Agent
    - 9.1.3.1.2 Canada: Peripheral Liquid Embolic Agents Market Breakdown, by Application
  - 9.1.3.2 Mexico: Peripheral Liquid Embolic Agents Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 9.1.3.2.1 Mexico: Peripheral Liquid Embolic Agents Market Breakdown, by Type
    - 9.1.3.2.1.1 Mexico: Peripheral Liquid Embolic Agents Market Breakdown, by Polymerizing Liquid Embolic Agent
    - 9.1.3.2.1.2 Mexico: Peripheral Liquid Embolic Agents Market Breakdown, by Precipitating Liquid Embolic Agent
    - 9.1.3.2.2 Mexico: Peripheral Liquid Embolic Agents Market Breakdown, by Application
9.2 Europe
- 9.2.1 Europe Peripheral Liquid Embolic Agents Market Overview
- 9.2.2 Europe: Peripheral Liquid Embolic Agents Market - Revenue and Forecast to 2031 (US$ Thousand)
  - 9.2.2.1 Europe: Peripheral Liquid Embolic Agents Market - Revenue and Forecast Analysis - by Type
  - 9.2.2.2 Europe: Peripheral Liquid Embolic Agents Market - Volume and Forecast Analysis - by Type
    - 9.2.2.2.1 Europe: Peripheral Liquid Embolic Agents Market - Revenue and Forecast Analysis - by Polymerizing Liquid Embolic Agent
    - 9.2.2.2.2 Europe: Peripheral Liquid Embolic Agents Market - Volume and Forecast Analysis - by Polymerizing Liquid Embolic Agent
    - 9.2.2.2.3 Europe: Peripheral Liquid Embolic Agents Market - Revenue and Forecast Analysis - by Precipitating Liquid Embolic Agent
    - 9.2.2.2.4 Europe: Peripheral Liquid Embolic Agents Market - Volume and Forecast Analysis - by Precipitating Liquid Embolic Agent
  - 9.2.2.3 Europe: Peripheral Liquid Embolic Agents Market - Revenue and Forecast Analysis - by Application
- 9.2.3 Europe: Peripheral Liquid Embolic Agents Market - Revenue and Forecast Analysis - by Country
  - 9.2.3.1 Germany: Peripheral Liquid Embolic Agents Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 9.2.3.1.1 Germany: Peripheral Liquid Embolic Agents Market Breakdown, by Type
    - 9.2.3.1.1.1 Germany: Peripheral Liquid Embolic Agents Market Breakdown, by Polymerizing Liquid Embolic Agent
    - 9.2.3.1.1.2 Germany: Peripheral Liquid Embolic Agents Market Breakdown, by Precipitating Liquid Embolic Agent
    - 9.2.3.1.2 Germany: Peripheral Liquid Embolic Agents Market Breakdown, by Application
  - 9.2.3.2 United Kingdom: Peripheral Liquid Embolic Agents Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 9.2.3.2.1 United Kingdom: Peripheral Liquid Embolic Agents Market Breakdown, by Type
    - 9.2.3.2.1.1 United Kingdom: Peripheral Liquid Embolic Agents Market Breakdown, by Polymerizing Liquid Embolic Agent
    - 9.2.3.2.1.2 United Kingdom: Peripheral Liquid Embolic Agents Market Breakdown, by Precipitating Liquid Embolic Agent
    - 9.2.3.2.2 United Kingdom: Peripheral Liquid Embolic Agents Market Breakdown, by Application
  - 9.2.3.3 France: Peripheral Liquid Embolic Agents Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 9.2.3.3.1 France: Peripheral Liquid Embolic Agents Market Breakdown, by Type
    - 9.2.3.3.1.1 France: Peripheral Liquid Embolic Agents Market Breakdown, by Polymerizing Liquid Embolic Agent
    - 9.2.3.3.1.2 France: Peripheral Liquid Embolic Agents Market Breakdown, by Precipitating Liquid Embolic Agent
    - 9.2.3.3.2 France: Peripheral Liquid Embolic Agents Market Breakdown, by Application
  - 9.2.3.4 Italy: Peripheral Liquid Embolic Agents Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 9.2.3.4.1 Italy: Peripheral Liquid Embolic Agents Market Breakdown, by Type
    - 9.2.3.4.1.1 Italy: Peripheral Liquid Embolic Agents Market Breakdown, by Polymerizing Liquid Embolic Agent
    - 9.2.3.4.1.2 Italy: Peripheral Liquid Embolic Agents Market Breakdown, by Precipitating Liquid Embolic Agent
    - 9.2.3.4.2 Italy: Peripheral Liquid Embolic Agents Market Breakdown, by Application
  - 9.2.3.5 Spain: Peripheral Liquid Embolic Agents Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 9.2.3.5.1 Spain: Peripheral Liquid Embolic Agents Market Breakdown, by Type
    - 9.2.3.5.1.1 Spain: Peripheral Liquid Embolic Agents Market Breakdown, by Polymerizing Liquid Embolic Agent
    - 9.2.3.5.1.2 Spain: Peripheral Liquid Embolic Agents Market Breakdown, by Precipitating Liquid Embolic Agent
    - 9.2.3.5.2 Spain: Peripheral Liquid Embolic Agents Market Breakdown, by Application
  - 9.2.3.6 Rest of Europe: Peripheral Liquid Embolic Agents Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 9.2.3.6.1 Rest of Europe: Peripheral Liquid Embolic Agents Market Breakdown, by Type
    - 9.2.3.6.1.1 Rest of Europe: Peripheral Liquid Embolic Agents Market Breakdown, by Polymerizing Liquid Embolic Agent
    - 9.2.3.6.1.2 Rest of Europe: Peripheral Liquid Embolic Agents Market Breakdown, by Precipitating Liquid Embolic Agent
    - 9.2.3.6.2 Rest of Europe: Peripheral Liquid Embolic Agents Market Breakdown, by Application
9.3 Asia Pacific
- 9.3.1 Asia Pacific Peripheral Liquid Embolic Agents Market Overview
- 9.3.2 Asia Pacific: Peripheral Liquid Embolic Agents Market - Revenue and Forecast to 2031 (US$ Thousand)
  - 9.3.2.1 Asia Pacific: Peripheral Liquid Embolic Agents Market - Revenue and Forecast Analysis - by Type
  - 9.3.2.2 Asia Pacific: Peripheral Liquid Embolic Agents Market - Volume and Forecast Analysis - by Type
    - 9.3.2.2.1 Asia Pacific: Peripheral Liquid Embolic Agents Market - Revenue and Forecast Analysis - by Polymerizing Liquid Embolic Agent
    - 9.3.2.2.2 Asia Pacific: Peripheral Liquid Embolic Agents Market - Volume and Forecast Analysis - by Polymerizing Liquid Embolic Agent
    - 9.3.2.2.3 Asia Pacific: Peripheral Liquid Embolic Agents Market - Revenue and Forecast Analysis - by Precipitating Liquid Embolic Agent
    - 9.3.2.2.4 Asia Pacific: Peripheral Liquid Embolic Agents Market - Volume and Forecast Analysis - by Precipitating Liquid Embolic Agent
  - 9.3.2.3 Asia Pacific: Peripheral Liquid Embolic Agents Market - Revenue and Forecast Analysis - by Application
- 9.3.3 Asia Pacific: Peripheral Liquid Embolic Agents Market - Revenue and Forecast Analysis - by Country
  - 9.3.3.1 China: Peripheral Liquid Embolic Agents Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 9.3.3.1.1 China: Peripheral Liquid Embolic Agents Market Breakdown, by Type
    - 9.3.3.1.1.1 China: Peripheral Liquid Embolic Agents Market Breakdown, by Polymerizing Liquid Embolic Agent
    - 9.3.3.1.1.2 China: Peripheral Liquid Embolic Agents Market Breakdown, by Precipitating Liquid Embolic Agent
    - 9.3.3.1.2 China: Peripheral Liquid Embolic Agents Market Breakdown, by Application
  - 9.3.3.2 Japan: Peripheral Liquid Embolic Agents Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 9.3.3.2.1 Japan: Peripheral Liquid Embolic Agents Market Breakdown, by Type
    - 9.3.3.2.1.1 Japan: Peripheral Liquid Embolic Agents Market Breakdown, by Polymerizing Liquid Embolic Agent
    - 9.3.3.2.1.2 Japan: Peripheral Liquid Embolic Agents Market Breakdown, by Precipitating Liquid Embolic Agent
    - 9.3.3.2.2 Japan: Peripheral Liquid Embolic Agents Market Breakdown, by Application
  - 9.3.3.3 India: Peripheral Liquid Embolic Agents Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 9.3.3.3.1 India: Peripheral Liquid Embolic Agents Market Breakdown, by Type
    - 9.3.3.3.1.1 India: Peripheral Liquid Embolic Agents Market Breakdown, by Polymerizing Liquid Embolic Agent
    - 9.3.3.3.1.2 India: Peripheral Liquid Embolic Agents Market Breakdown, by Precipitating Liquid Embolic Agent
    - 9.3.3.3.2 India: Peripheral Liquid Embolic Agents Market Breakdown, by Application
  - 9.3.3.4 Australia: Peripheral Liquid Embolic Agents Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 9.3.3.4.1 Australia: Peripheral Liquid Embolic Agents Market Breakdown, by Type
    - 9.3.3.4.1.1 Australia: Peripheral Liquid Embolic Agents Market Breakdown, by Polymerizing Liquid Embolic Agent
    - 9.3.3.4.1.2 Australia: Peripheral Liquid Embolic Agents Market Breakdown, by Precipitating Liquid Embolic Agent
    - 9.3.3.4.2 Australia: Peripheral Liquid Embolic Agents Market Breakdown, by Application
  - 9.3.3.5 South Korea: Peripheral Liquid Embolic Agents Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 9.3.3.5.1 South Korea: Peripheral Liquid Embolic Agents Market Breakdown, by Type
    - 9.3.3.5.1.1 South Korea: Peripheral Liquid Embolic Agents Market Breakdown, by Polymerizing Liquid Embolic Agent
    - 9.3.3.5.1.2 South Korea: Peripheral Liquid Embolic Agents Market Breakdown, by Precipitating Liquid Embolic Agent
    - 9.3.3.5.2 South Korea: Peripheral Liquid Embolic Agents Market Breakdown, by Application
  - 9.3.3.6 Rest of APAC: Peripheral Liquid Embolic Agents Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 9.3.3.6.1 Rest of APAC: Peripheral Liquid Embolic Agents Market Breakdown, by Type
    - 9.3.3.6.1.1 Rest of APAC: Peripheral Liquid Embolic Agents Market Breakdown, by Polymerizing Liquid Embolic Agent
    - 9.3.3.6.1.2 Rest of APAC: Peripheral Liquid Embolic Agents Market Breakdown, by Precipitating Liquid Embolic Agent
    - 9.3.3.6.2 Rest of APAC: Peripheral Liquid Embolic Agents Market Breakdown, by Application
9.4 Middle East & Africa
- 9.4.1 Middle East & Africa Peripheral Liquid Embolic Agents Market Overview
- 9.4.2 Middle East & Africa: Peripheral Liquid Embolic Agents Market - Revenue and Forecast to 2031 (US$ Thousand)
  - 9.4.2.1 Middle East & Africa: Peripheral Liquid Embolic Agents Market - Revenue and Forecast Analysis - by Type
  - 9.4.2.2 Middle East & Africa: Peripheral Liquid Embolic Agents Market - Volume and Forecast Analysis - by Type
    - 9.4.2.2.1 Middle East & Africa: Peripheral Liquid Embolic Agents Market - Revenue and Forecast Analysis - by Polymerizing Liquid Embolic Agent
    - 9.4.2.2.2 Middle East & Africa: Peripheral Liquid Embolic Agents Market - Volume and Forecast Analysis - by Polymerizing Liquid Embolic Agent
    - 9.4.2.2.3 Middle East & Africa: Peripheral Liquid Embolic Agents Market - Revenue and Forecast Analysis - by Precipitating Liquid Embolic Agent
    - 9.4.2.2.4 Middle East & Africa: Peripheral Liquid Embolic Agents Market - Volume and Forecast Analysis - by Precipitating Liquid Embolic Agent
  - 9.4.2.3 Middle East & Africa: Peripheral Liquid Embolic Agents Market - Revenue and Forecast Analysis - by Application
- 9.4.3 Middle East & Africa: Peripheral Liquid Embolic Agents Market - Revenue and Forecast Analysis - by Country
  - 9.4.3.1 Saudi Arabia: Peripheral Liquid Embolic Agents Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 9.4.3.1.1 Saudi Arabia: Peripheral Liquid Embolic Agents Market Breakdown, by Type
    - 9.4.3.1.1.1 Saudi Arabia: Peripheral Liquid Embolic Agents Market Breakdown, by Polymerizing Liquid Embolic Agent
    - 9.4.3.1.1.2 Saudi Arabia: Peripheral Liquid Embolic Agents Market Breakdown, by Precipitating Liquid Embolic Agent
    - 9.4.3.1.2 Saudi Arabia: Peripheral Liquid Embolic Agents Market Breakdown, by Application
  - 9.4.3.2 South Africa: Peripheral Liquid Embolic Agents Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 9.4.3.2.1 South Africa: Peripheral Liquid Embolic Agents Market Breakdown, by Type
    - 9.4.3.2.1.1 South Africa: Peripheral Liquid Embolic Agents Market Breakdown, by Polymerizing Liquid Embolic Agent
    - 9.4.3.2.1.2 South Africa: Peripheral Liquid Embolic Agents Market Breakdown, by Precipitating Liquid Embolic Agent
    - 9.4.3.2.2 South Africa: Peripheral Liquid Embolic Agents Market Breakdown, by Application
  - 9.4.3.3 United Arab Emirates: Peripheral Liquid Embolic Agents Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 9.4.3.3.1 United Arab Emirates: Peripheral Liquid Embolic Agents Market Breakdown, by Type
    - 9.4.3.3.1.1 United Arab Emirates: Peripheral Liquid Embolic Agents Market Breakdown, by Polymerizing Liquid Embolic Agent
    - 9.4.3.3.1.2 United Arab Emirates: Peripheral Liquid Embolic Agents Market Breakdown, by Precipitating Liquid Embolic Agent
    - 9.4.3.3.2 United Arab Emirates: Peripheral Liquid Embolic Agents Market Breakdown, by Application
  - 9.4.3.4 Rest of Middle East & Africa: Peripheral Liquid Embolic Agents Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 9.4.3.4.1 Rest of Middle East & Africa: Peripheral Liquid Embolic Agents Market Breakdown, by Type
    - 9.4.3.4.1.1 Rest of Middle East & Africa: Peripheral Liquid Embolic Agents Market Breakdown, by Polymerizing Liquid Embolic Agent
    - 9.4.3.4.1.2 Rest of Middle East & Africa: Peripheral Liquid Embolic Agents Market Breakdown, by Precipitating Liquid Embolic Agent
    - 9.4.3.4.2 Rest of Middle East & Africa: Peripheral Liquid Embolic Agents Market Breakdown, by Application
9.5 South and Central America
- 9.5.1 South and Central America Peripheral Liquid Embolic Agents Market Overview
- 9.5.2 South and Central America: Peripheral Liquid Embolic Agents Market - Revenue and Forecast to 2031 (US$ Thousand)
  - 9.5.2.1 South and Central America: Peripheral Liquid Embolic Agents Market - Revenue and Forecast Analysis - by Type
  - 9.5.2.2 South and Central America: Peripheral Liquid Embolic Agents Market - Volume and Forecast Analysis - by Type
    - 9.5.2.2.1 South and Central America: Peripheral Liquid Embolic Agents Market - Revenue and Forecast Analysis - by Polymerizing Liquid Embolic Agent
    - 9.5.2.2.2 South and Central America: Peripheral Liquid Embolic Agents Market - Volume and Forecast Analysis - by Polymerizing Liquid Embolic Agent
    - 9.5.2.2.3 South and Central America: Peripheral Liquid Embolic Agents Market - Revenue and Forecast Analysis - by Precipitating Liquid Embolic Agent
    - 9.5.2.2.4 South and Central America: Peripheral Liquid Embolic Agents Market - Volume and Forecast Analysis - by Precipitating Liquid Embolic Agent
  - 9.5.2.3 South and Central America: Peripheral Liquid Embolic Agents Market - Revenue and Forecast Analysis - by Application
- 9.5.3 South and Central America: Peripheral Liquid Embolic Agents Market - Revenue and Forecast Analysis - by Country
  - 9.5.3.1 Brazil: Peripheral Liquid Embolic Agents Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 9.5.3.1.1 Brazil: Peripheral Liquid Embolic Agents Market Breakdown, by Type
    - 9.5.3.1.1.1 Brazil: Peripheral Liquid Embolic Agents Market Breakdown, by Polymerizing Liquid Embolic Agent
    - 9.5.3.1.1.2 Brazil: Peripheral Liquid Embolic Agents Market Breakdown, by Precipitating Liquid Embolic Agent
    - 9.5.3.1.2 Brazil: Peripheral Liquid Embolic Agents Market Breakdown, by Application
  - 9.5.3.2 Argentina: Peripheral Liquid Embolic Agents Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 9.5.3.2.1 Argentina: Peripheral Liquid Embolic Agents Market Breakdown, by Type
    - 9.5.3.2.1.1 Argentina: Peripheral Liquid Embolic Agents Market Breakdown, by Polymerizing Liquid Embolic Agent
    - 9.5.3.2.1.2 Argentina: Peripheral Liquid Embolic Agents Market Breakdown, by Precipitating Liquid Embolic Agent
    - 9.5.3.2.2 Argentina: Peripheral Liquid Embolic Agents Market Breakdown, by Application
  - 9.5.3.3 Rest of South and Central America: Peripheral Liquid Embolic Agents Market - Revenue and Forecast to 2031 (US$ Thousand)
    - 9.5.3.3.1 Rest of South and Central America: Peripheral Liquid Embolic Agents Market Breakdown, by Type
    - 9.5.3.3.1.1 Rest of South and Central America: Peripheral Liquid Embolic Agents Market Breakdown, by Polymerizing Liquid Embolic Agent
    - 9.5.3.3.1.2 Rest of South and Central America: Peripheral Liquid Embolic Agents Market Breakdown, by Precipitating Liquid Embolic Agent
    - 9.5.3.3.2 Rest of South and Central America: Peripheral Liquid Embolic Agents Market Breakdown, by Application

10. Industry Landscape

10.1 Overview
10.2 Growth Strategies in the Peripheral Liquid Embolic Agents Market
10.3 Inorganic Growth Strategies
- 10.3.1 Overview
10.4 Organic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 Medtronic Plc
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 B Braun SE
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Guerbet SA
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Sirtex Medical Ltd
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Balt
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 MicroVention Inc
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Johnson & Johnson
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 GEM srl
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments

12. Appendix

12.1 About The Insight Partners
12.2 Glossary of Terms